Tjitra Emiliana, Baker Joanne, Suprianto Sri, Cheng Qin, Anstey Nicholas M
National Institute of Health Research and Development, Ministry of Health, Australia.
Antimicrob Agents Chemother. 2002 Dec;46(12):3947-53. doi: 10.1128/AAC.46.12.3947-3953.2002.
Artemisinin-derivative combination therapies (ACT) are highly efficacious against multidrug-resistant Plasmodium falciparum malaria. Few efficacy data, however, are available for vivax malaria. With high rates of chloroquine (CQ) resistance in both vivax and falciparum malaria in Papua Province, Indonesia, new combination therapies are required for both species. We recently found artesunate plus sulfadoxine-pyrimethamine (ART-SP) to be highly effective (96%) in the treatment of falciparum malaria in Papua Province. Following a preliminary study of CQ plus sulfadoxine-pyrimethamine (CQ-SP) for the treatment of Plasmodium vivax infection, we used modified World Health Organization criteria to evaluate the efficacy of ART-SP for the treatment of vivax malaria in Papua. Nineteen of 22 patients treated with ART-SP could be evaluated on day 28, with no early treatment failures. Adequate clinical and parasitological responses were found by day 14 in all 20 (100%) of the patients able to be evaluated and by day 28 in 17 patients (89.5%). Fever and parasite clearance times were short, with hematological improvement observed in 70.6% of the patients. Double (at positions 58 and 117) and quadruple (at positions 57, 58, 61, and 117) mutations in the P. vivax dihydrofolate reductase (PvDHFR) were common in Papuan P. vivax isolates (46 and 18%, respectively). Treatment failure with SP-containing regimens was significantly higher with isolates with this PvDHFR quadruple mutation, which included a novel T-->M mutation at residue 61 linked to an S-->T (but not an S-->N) mutation at residue 117. ART-SP ACT resulted in a high cure rate for both major Plasmodium species in Papua, though progression of DHFR mutations in both species due to the continued use of SP monotherapy for clinically diagnosed malaria threatens the future utility of this combination.
青蒿素衍生物联合疗法(ACT)对耐多药恶性疟原虫疟疾具有高效。然而,间日疟的疗效数据却很少。在印度尼西亚巴布亚省,间日疟和恶性疟对氯喹(CQ)均有较高的耐药率,因此这两种疟原虫都需要新的联合疗法。我们最近发现,青蒿琥酯加磺胺多辛-乙胺嘧啶(ART-SP)在治疗巴布亚省的恶性疟方面非常有效(96%)。在对CQ加磺胺多辛-乙胺嘧啶(CQ-SP)治疗间日疟原虫感染进行初步研究之后,我们采用修改后的世界卫生组织标准来评估ART-SP治疗巴布亚间日疟的疗效。接受ART-SP治疗的22例患者中有19例在第28天可进行评估,无早期治疗失败病例。在所有20例(100%)可评估的患者中,第14天时均出现了充分的临床和寄生虫学反应,17例患者(89.5%)在第28天时出现了上述反应。发热和寄生虫清除时间较短,70.6%的患者血液学状况有所改善。间日疟二氢叶酸还原酶(PvDHFR)的双突变(第58和117位)和四突变(第57、58、61和117位)在巴布亚间日疟原虫分离株中很常见(分别为46%和18%)。含SP方案治疗失败在具有这种PvDHFR四突变的分离株中显著更高,该突变包括第61位的一个新的T→M突变,与第117位的S→T(而非S→N)突变相关。ART-SP联合疗法在巴布亚对两种主要疟原虫均产生了较高的治愈率,不过由于对临床诊断的疟疾持续使用SP单药治疗,两种疟原虫的DHFR突变进展威胁到了这种联合疗法未来的效用。